Inovio

529 articles about Inovio

• INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

  3/1/2021

  INOVIO, (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial

• INOVIO to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

  2/16/2021

   INOVIO (NASDAQ: INO) announced today that fourth quarter and year-end 2020 financial results will be released after the market close on March 1, 2021 .

• INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

  1/6/2021

  - DNA immunotherapy candidate VGX-3100 demonstrated clinically significant reduction of HPV-16/18-associated precancerous vulvar lesions in 63% of treated participants six months after treatment - Phase 2 results indicate that VGX-3100 can be a safe, tolerable and efficacious adjunct to current standard of care for women with vulvar dysplasia - Phase 3 trial planned in 2021

• INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China

  1/4/2021

  INOVIO (NASDAQ: INO), and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine"), today announced that they have entered into a collaboration and license agreement for COVID-19 DNA vaccine candidate INO-4800.

• INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine

  12/24/2020

  Peer-reviewed Phase 1 data shows INO-4800 to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses INO-4800 demonstrates favorable safety and tolerability, with no serious adverse events reported Offers best-in-class thermostability, including a five-year projected shelf life at normal refrigeration temperature and no frozen transport or storage requirements

• INOVIO to Develop DNA-encoded Monoclonal Antibody (dMAb®) Candidates to Treat COVID-19 with Funding from the Defense Advanced Research Projects Agency (DARPA)

  12/15/2020

  - DARPA to fund innovative public-private partnership between INOVIO, The Wistar Institute, AstraZeneca, the University of Pennsylvania and Indiana University - $37.6 million grant from DARPA will leverage AstraZeneca's monoclonal antibody and INOVIO's DNA-encoded monoclonal antibody (dMAb®) technologies in the fight against COVID-19

• 

  COVID News Alert: At-Home Test Approved, FDA Panel Meets on Pfizer Vaccine and More

  12/10/2020

  All eyes on the FDA as they review a COVID-19 vaccine, FDA approval of an Emergency Use Authorization to LabCorp’s home test kit for COVID-19, the first testing device that does not require a prescription and more news.

• INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.

  12/3/2020

  INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the execution of an agreement with Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation, for Eurogentec to manufacture INOVIO's COVID-19 vaccine candidate INO-4800 at their industry-leading GMP plasmid production scales

• INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)

  11/23/2020

   INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject with DNA medicine INO-3107 in a Phase 1/2 clinical trial for the treatment of Recurrent Respiratory Papi

• INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Meeting

  11/20/2020

  Interim review in newly diagnosed glioblastoma patients provides OS18 data, demonstrates immunogenicity and tolerability in a majority of patients

• INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense

  11/16/2020

   INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to proceed with the Phase 2 segment of its planned Pha

• INOVIO Reports Third Quarter 2020 Financial Results

  11/9/2020

  INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended September 30, 2020.

• INOVIO to Report Third Quarter 2020 Financial Results on November 9, 2020

  10/26/2020

   INOVIO (NASDAQ: INO) announced today that third quarter 2020 financial results will be released after the market close on November 9, 2020 . Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA M

• INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800

  9/28/2020

  INOVIO announced that the U.S. Food and Drug Administration has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial.

• INOVIO Adds Thermo Fisher Scientific To Global Manufacturing Consortium

  9/8/2020

  INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Thermo Fisher Scientific, the world leader in serving science, has signed a letter of intent to manufacture INOVIO's DNA COVID-19 vaccine candidate INO-4800.

• INOVIO to Present at Upcoming Investor Conferences in September

  9/1/2020

  INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Dr. J. Joseph Kim, President and CEO, along with other members of INOVIO management, will present at the following investor conferences in September:

• INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus

  7/30/2020

  - INO-4800 showed durable antibody and T cell responses in rhesus macaques for 4 months - INO-4800 is the only vaccine to demonstrate long-term protection in non-human primates challenged with SARS-CoV-2 virus 13 weeks from vaccination - Memory T and B cell responses resulted in reduced viral loads and faster viral clearance in macaques' lungs and nasal passages - INO-4800 vaccination generated antibodies neutralizing both the earlier strain of virus as well as the

• INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP)

  7/29/2020

   INOVIO (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis (RRP). RRP is a rare disease caused by human papillomavirus (HPV) types 6 and 11 infec

• INOVIO to Report Second Quarter 2020 Financial Results on August 10, 2020

  7/27/2020

  INOVIO (NASDAQ: INO) announced today that second quarter 2020 financial results will be released after the market close on August 10, 2020 . Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update, including the company

• 

  Clinical Catch-Up: June 29-July 3

  7/6/2020

  Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.